WO2012016886A2 - Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant - Google Patents

Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant Download PDF

Info

Publication number
WO2012016886A2
WO2012016886A2 PCT/EP2011/062853 EP2011062853W WO2012016886A2 WO 2012016886 A2 WO2012016886 A2 WO 2012016886A2 EP 2011062853 W EP2011062853 W EP 2011062853W WO 2012016886 A2 WO2012016886 A2 WO 2012016886A2
Authority
WO
WIPO (PCT)
Prior art keywords
lattice structure
coating
implant
aorta
aortic
Prior art date
Application number
PCT/EP2011/062853
Other languages
German (de)
English (en)
Other versions
WO2012016886A3 (fr
Inventor
Hans Reiner Figulla
Alexander Lauten
Original Assignee
Hans Reiner Figulla
Alexander Lauten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Reiner Figulla, Alexander Lauten filed Critical Hans Reiner Figulla
Publication of WO2012016886A2 publication Critical patent/WO2012016886A2/fr
Publication of WO2012016886A3 publication Critical patent/WO2012016886A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
    • A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Definitions

  • the invention relates to a medical implant for endovascular stabilization or reinforcement of vessel walls, such as the wall of the aorta, in particular the ascending aorta, and to a method for producing such an implant.
  • a common disease of the cardiovascular system is aneurysms, especially aortic aneurysms. Prerequisite for the
  • the vascular walls in the human body are made up of several tissue layers.
  • the tissue layer lining the vessel wall inside is called intima.
  • the intima comprises in particular epithelial cells, specifically cells of the
  • the intima is further encased by the media as a second layer of tissue.
  • the media comprises muscle fiber cells which are an expansion or Can cause narrowing of the vessels.
  • the media In arterial vessels, such as the aorta, the media is comparatively thick, whereas venous vessels comprise a thin muscle layer or media.
  • the blood supply of the media takes place mainly from the lumen of the blood vessel, especially the aorta. Specifically, the cells of the media are involved in diffusion processes between the blood carried within the blood vessel and the media
  • Elastin is responsible for the shaping and the maintenance of the vessel wall structure. Overall, the aforementioned degenerative processes can lead to a weakening of the vessel wall, causing the development of aneurysms, ie
  • aortic aneurysms In addition to degenerative processes, aortic aneurysms often develop due to congenital or congenital connective tissue diseases.
  • Marfan syndrome due to an autosomal dominant inheritance mutation of fibrillation to change the ultrastructure of the microfibrils of the connective tissue and thus in the arterial vascular system to progressive
  • aneurysmal dilatations Left untreated, these aneurysmal dilations can lead to dissection or rupture of the vessels, such as the aorta. Often the aneurysmal extensions are therefore responsible for lethal complications in young age.
  • untreated aneurysms such as aortic aneurysms
  • the weakened vessel wall is subject to increased wall stress according to Laplace's law. Therefore, the risk of rupture increases with increasing
  • aneurysms in particular aneurysms of the thoracic aorta, is performed by surgical vascular replacement (eg, aortic replacement), whereby a part of the vessel (aorta) is replaced by a vascular prosthesis.
  • surgical vascular replacement eg, aortic replacement
  • aortic replacement e.g, aortic replacement
  • aorta a part of the vessel
  • Implantation of an endograf to treat Both known therapeutic methods are carried out after exceeding a critical vessel diameter or after the occurrence of a complication. This is to ensure that the
  • the vascular prosthesis creates a new lumen or flow passage for blood flow.
  • the ectatic site in the area of the aneurysm is thereby freed from the pressure of the blood flow, thus reducing the risk of rupture.
  • the object of the invention is to provide a medical implant for
  • the object of the invention is to provide a method for producing such an implant.
  • the invention is based on the idea of a medical implant for
  • endovascular stabilization vessel walls especially the aortic wall
  • the grid structure is self-expandable and has a
  • the coating acts in an implanted state
  • the method according to the invention or the implant according to the invention is suitable for the stabilization of all vascular diseases. Accordingly, the method according to the invention can also be used, for example, for the treatment of all peripheral vessels (for example, arteries in the legs, arms, kidneys and in the shark) as well as coronary vessels.
  • peripheral vessels for example, arteries in the legs, arms, kidneys and in the shark
  • the invention is based on the idea of providing a medical implant which enables a stabilization of vessel walls, in particular of the aortic wall, before an aneurysm (eg aortic aneurysm) can form.
  • the implant comprises a grid structure which is compressible and expandable. The expansion of the lattice structure takes place automatically.
  • the implant or the lattice structure of the implant is self-expandable.
  • the implant serves for endovascular support or stabilization of the vessel wall, in particular the aortic wall.
  • the implantation is thus minimally invasive by a delivery system that is guided within the Blutgfäßes (eg aorta) to the treatment site. A major surgery is not required.
  • the implant according to the invention thus makes possible a preventive therapy of
  • aneurysms such as aortic aneurysms, with low operative risks for the patient.
  • the implant according to the invention is provided with a coating which interacts with the vessel wall (for example aortic wall) in the implanted state.
  • the coating is such that it interacts with the vessel wall (aortic wall), in particular the biological tissue of the vessel wall (aortic wall), preferably the intima and / or the media, to allow ingrowth of the lattice structure into the vessel wall (aortic wall).
  • Coating cell-growth-promoting trained The coating allows a connection between the lattice structure and the biological tissue of the vessel wall (aortic wall). Thus, a tolerable and rapid integration of the implant in the vessel wall (aortic wall) is achieved.
  • the implant according to the invention forms a support framework for the vessel wall (eg aortic wall), which inserts itself into the tissue structure of the vessel wall (aortic wall) and thus leads to a stabilization and reinforcement of the vessel wall (aortic wall).
  • the grid structure has a sufficient
  • the lattice structure can follow the changes in the cross-sectional diameter of the blood vessel, such as the aorta, during systole and diastole.
  • different parameters of the lattice structure can be varied.
  • the cell size or mesh size, the web dimensions, for example web width or depth or web length, and / or the layer thickness of the coating can be adjusted accordingly.
  • the flexibility or elasticity of the grid structure by an appropriate choice of material for the webs or the
  • the implant according to the invention induces or promotes fibrosis, ie the increase in connective tissue.
  • the implant with the vessel wall eg, aortic wall
  • the use of the implant according to the invention is possible, for example, in the entire aorta or in all sections of the aorta, in particular the ascending aorta, the aortic arch and the descending aorta.
  • the tubular lattice structure in an expanded state in particular in
  • the tubular lattice structure in the manufacturing state is so oversized that it is greater than the aforementioned percentages greater than the inner diameter of the vessel portion of the aorta, in which the implant is to be used in kraftunbelasteten state, ie without the action of external forces. In this way it is ensured that the
  • Lattice structure has a comparatively low radial force.
  • a comparatively low radial force makes it possible for the lattice structure to adapt well to the movements of the aorta, in particular during systole and diastole. Furthermore, the low radial force prevents excessive stiffening of the blood vessel, such as, for example, the aorta. For example, it can be ensured that the aorta's vesicular function is maintained even after being supported by the medical implant.
  • the coating preferably encloses a number of webs of the lattice structure.
  • the coated webs of the lattice structure are completely enclosed by biological tissue.
  • the endotelialization of the lattice structure should extend completely over the ridge surface of the structure.
  • the complete coating of the webs of the lattice structure an improved ingrowth of the lattice structure into the vessel wall (aortic wall).
  • the coating may partially or completely cover the grid structure, with the cells of the grid structure kept free.
  • the lattice structure has a comparatively small total surface area. It is therefore advantageous to keep the cells of the lattice structure or the cell openings free from the coating.
  • the coating thus concentrates on the webs or the web surfaces of the lattice structure.
  • the coating may cover the lattice structure partially or completely. That means the
  • Grid structure may have portions which are provided with the coating. Other sections of the lattice structure may be formed without coatings. In other words, the lattice structure may have webs or web areas which are provided with the coating, whereas further webs or web areas
  • Grid structure has partially different coatings.
  • Coating materials and / or different layer thicknesses of the coating differ. For example, different layer thicknesses of
  • Blood vessel such as in the aorta, are taken into account.
  • the lattice structure may be formed such that portions of the lattice structure implanted in areas of blood vessel, particularly the aorta, having a smaller wall thickness than other areas of the blood vessel, which are also supported by the lattice structure, grow slower or faster into the vessel wall or integrated into the vessel wall.
  • portions of the lattice structure implanted in areas of blood vessel, particularly the aorta, having a smaller wall thickness than other areas of the blood vessel, which are also supported by the lattice structure grow slower or faster into the vessel wall or integrated into the vessel wall.
  • the layer thickness of the coating or coating materials the skilled person selects based on the respective
  • the coating comprises a biocompatible plastic, in particular polyurethane or polycarbonate urethane, or a biological material, in particular a
  • Grid structure and encloses this.
  • the lattice structure or, more generally, the implant with the vessel wall such.
  • the vascular wall of the aorta a solid unit, whereby the mechanical strength of the vessel wall increases.
  • Synthesis of the collagen-rich matrix or ingrowth of the lattice structure into the vessel wall can be promoted by a suitable biocompatible coating. It has been shown that in particular plastic coatings of polyurethane or polycarbonate urethane favor ingrowth of the lattice structure.
  • a biological material for coating the lattice structure can be used, which also causes ingrowth of the lattice structure or a firm connection between vessel wall and lattice structure.
  • the biological material may include, for example, endogenous stem cells.
  • the coating performs the function of a matrix for the penetration of
  • Collagen fibers and / or fibroblasts to allow a solid unit between the coating or the lattice structure and the intima and media of the vessel wall.
  • the plastics polyurethane and polycarbonate urethane are particularly suitable for the production of the coating, since these are easily and homogeneously connectable to the webs of the lattice structure.
  • the use of polyurethane or polycarbonate urethane makes it possible to apply a homogeneous and comparatively thin coating to the webs of the lattice structure.
  • the use of biocompatible plastics fundamentally allows the use of dip or spray coating methods, which allow a particularly simple and rapid production of the implant with high accuracy and adjustability of the layer thicknesses of the coating. It is also possible that the lattice structure is formed completely free of coating.
  • Adapted lattice structure a growth of tissue cells of the vessel wall, For example, the aortic wall, to promote.
  • the grid structure is therefore surface-treated.
  • the overall surface of the lattice structure or of the webs may comprise a structuring, preferably a porous structure or pore structure.
  • the lattice structure preferably comprises a biocompatible shape memory material, in particular a shape memory metal or a shape memory polymer.
  • Shape memory metal is preferably a nickel-titanium alloy provided. Such materials enable the production of a self-expandable
  • Lattice structure Specifically, in shape memory materials, one causes
  • the lattice structure can be imprinted with a desired shape, which the lattice structure in over- or
  • Shape memory materials in particular shape memory alloys, have the further advantage that they can exhibit a pseudoelastic behavior.
  • the elasticity of the lattice structure is thus increased, the pseudoelastic behavior resulting from a structural change of the shape memory material.
  • the pseudo-elasticity causes the material to relieve itself by its internal tension in the original form when relieving.
  • the pseudoelastic behavior is in
  • the invention is based on the idea of specifying a method for producing a previously explained medical implant, wherein a self-expandable grid structure is provided which at least partially by immersion and / or spray coating with a
  • biocompatible plastic in particular polyurethane or polycarbonate urethane.
  • the cells of the lattice structure are kept free.
  • the inventive method allows for a particularly simple and fast production of the medical implant, wherein by the diving and / or
  • Spray coating a uniform, in particular homogeneous, coating is adjustable.
  • the lattice structure in particular the webs of the lattice structure, is completely coated. In this way it is ensured that the webs of the grid structure are completely encased with the plastic coating.
  • the ingrowth of the lattice structure into the vessel wall is thus improved over the entire length and extent of the lattice structure.
  • implant according to the invention is used according to a preferred embodiment.
  • the single figure shows a cross-sectional representation of a human heart 30 and the aorta ascendens 21.
  • the heart 30 specifically the left ventricle, arises from the aorta or body artery.
  • the aortic valve 31 is arranged between the aorta and the left ventricle.
  • the aorta is divided into several sections.
  • the first section of the aorta following the aortic valve 31 is referred to as the ascending aorta or ascending aorta 21.
  • the aorta ascendens 21 merges into the aortic arch 22.
  • the branching vessels 23 essentially supply the upper one
  • the aortic arch 22 is adjoined by the descending aorta, which is oriented essentially parallel to the ascending aorta 21 and leads in the direction of the lower half of the body.
  • the descending aorta passes into the abdominal aorta or aorta abdominalis.
  • the aorta ascendens has one
  • Cross-sectional diameter or ectasia of the ascending aorta 21 may
  • the implant comprises a lattice structure 10, which can be converted from a compressed state into an expanded state.
  • the grid structure 10 can be guided in a supply system to the treatment location.
  • the delivery system is advantageously introduced into the body via the femoral artery and further into the aorta ascendens 21 via the abdominal aorta, the descending aorta and the aortic arch 22.
  • the implant is released from the delivery system, with the lattice structure 10 automatically expanding.
  • the lattice structure 10 is designed to be self-expandable.
  • the lattice structure 10 may include a shape memory alloy that occupies the previously impressed, expanded form at body temperature, that is approximately between 35 ° C and 38 ° C, in particular between 36 ° C and 37 ° C.
  • the lattice structure 10 adjoins the aortic wall 20 of the ascending aorta 21.
  • the lattice structure 10 has a radial force acting on the aortic wall 20.
  • the radial force is advantageously designed so small that on the one hand a full-surface contact with the aortic wall 20, in particular in cross-sectional changes of the aorta ascendens 21 in consequence of the pulse beat is ensured.
  • the radial force of the lattice structure is advantageously designed so small that on the one hand a full-surface contact with the aortic wall 20, in particular in cross-sectional changes of the aorta ascendens 21 in consequence of the pulse beat is ensured.
  • the lattice structure 10 set so small that a stiffening of the aortic wall 20 is reduced or avoided.
  • the lattice structure 10 is so flexible that the aortic wall 20 continues to essentially retain the natural vesicular function, that is, the elastic return for pressure equalization.
  • the lattice structure 10 is thus adapted in such a way that the compliance of the aorta ascendens 21 is essentially not impaired in terms of function.
  • the lattice structure 10 has cells 11 which are delimited by webs 12. The cells
  • the lattice structure 10 automatically expands to a cross-sectional diameter in a production state, that is to say in a force-unloaded state, which is at most 10%, in particular at most 9%, in particular at most 8%, in particular at most 7%, in particular at most 6% at most 5%,
  • the cross-sectional diameter of the lattice structure 10 in the implanted state corresponds to the inner diameter of the aorta or the ascending aorta 21.
  • the radial force can be adjusted by the mesh size or cell size of the cells 11.
  • the cells 11 preferably have a diamond-like shape.
  • the size and number of cells 11 influence the radial force of the lattice structure 10. Suitable values are known to the person skilled in the art and are selected according to the given requirements for the radial force.
  • the dimensions of the webs 12 provide further parameters for varying the radial force.
  • the web thickness of the webs and / or the web width of the webs 12 can be set such that the desired radial force is achieved.
  • the webs 12 have a web width in the range of micrometers.
  • the web thickness in the range of micrometers is provided.
  • the webs 12 may generally have different cross-sectional shapes.
  • the webs 12 a circular, oval or rectangular
  • Cross section include.
  • the webs 12 may be formed of wire elements which are intertwined to form the grid structure 10.
  • Lattice structure 10 allows a comparatively high mesh density or
  • the wire elements or webs 12 have a braiding angle which is comparatively small.
  • the acute angle is called, between a
  • Wire element and the longitudinal axis of the grid structure 10 is formed.
  • the lattice structure 10 or the webs 12 have a braiding angle which, in the production state, is at most 30 degrees, in particular at most 25 degrees, in particular at most 20 degrees, in particular at most 15 degrees, in particular at most 10 degrees. In this way, a particularly favorable radial force and flexibility of the grid structure is achieved.
  • the grid structure 10 is tubular.
  • the lattice structure 10 a is tubular.
  • the lattice structure 10 When implanted, the lattice structure may be curved to follow the shape of the aorta. It is also pointed out that the lattice structure 10 or generally the medical implant analogous to the embodiment shown in Figure 1 in other blood vessels, such as in the aortic arch 22 or in the descending aortic, can be used. The use of the
  • Implant in other blood vessels in particular the aortic arch 22, the descending aorta and all peripheral arteries, is therefore also disclosed and claimed within the scope of this application.
  • the lattice structure 10 may be formed as a whole stent-like. In other words, the grid structure 10 may form a stent.
  • the stent or the lattice structure 10 has a coating 13.
  • the coating 13 preferably surrounds the webs 12 or at least some of the webs 12.
  • the coating 13 preferably comprises a plastic, in particular
  • the coating is adapted such that penetration of collagen fibers and / or fibroblasts into the coating 13 is made possible.
  • the ingrowth of the lattice structure 10 can be assisted by the coating 13 having a cell growth-promoting surface.
  • the surface of the coating 13 is structured, for example.
  • the surface structure of the coating 13 may be made by a spray coating method.
  • the coating 13 may have pores which promote the attachment of
  • Collagen fibers and / or fibroblasts facilitate.
  • the coating 13 may be made by a dip coating method. It is possible that the coating 13 has multiple layers comprising different materials and / or structurings.
  • the coating 13 preferably has a layer thickness which, on the one hand, does not significantly affect the radial force of the lattice structure 10 and on the other hand favors an attachment of collagen fibers and fibroblasts.
  • the layer thickness of the coating 13 is preferably at most 10 micrometers, in particular at most 5 micrometers, in particular at most 1 micrometer, in particular at most 0.5 micrometer, in particular at most 0.1 micrometer.
  • the lattice structure 10 or the stent may have a plurality of sections, with a first section of the lattice structure 10 comprising the coating 13. The webs 12 of the first portion of the grid structure 10 are thus through the coating 13th
  • a second section of the lattice structure 10 may be formed without coatings. It is possible for the lattice structure 10 to have a plurality of sections that alternate with the coating 13 or coating-free
  • the sections of the lattice structure 10 may form ring segments which alternate in the longitudinal direction of the lattice structure 10.
  • the portions of the grid structure 10 may form strips extending in the longitudinal direction of the
  • Lattice structure 10 extend and alternate in the circumferential direction.
  • Portions of the grid structure 10 may also include free-form surfaces on the surface of the grid structure 10.
  • the sections of the grid structure 10 may also be different
  • Layer thicknesses of the coating 13 differ.
  • a first section of the lattice structure 10 may have a greater layer thickness of the coating 13 than a second section of the lattice structure 10.
  • the webs 12 and / or the cells 11 may have different dimensions in the different sections of the lattice structure 10.
  • the lattice structure 10 is preferably produced by providing a tubular solid material from which the cell openings or cells 11
  • the grid structure 10 may also be made by braiding wire elements.
  • the lattice structure 10 may be subjected to an etching process in a further, downstream process step in order to improve the adhesion of the coating 13.
  • the coating 13 is preferably by a dip and / or
  • the grid structure 10 is coated such that the coating 13, the webs 12 completely encased.
  • Preferred materials for the lattice structure 10 are shape memory alloys, in particular shape memory metal alloys. Particularly preferred is the
  • the lattice structure 10 may comprise a shape memory polymer.
  • the coating 13 comprises preferably polyurethane or polycarbonate urethane.
  • the coating 13 may comprise a biological material, for example a pericardial lining or the body's own stem cells.
  • the medical implant described here allows, for example, a preventive, minimally invasive therapy method for the treatment of thoracic aortic aneurysms, whereby the implantation of the self-expanding, coated lattice structure 10 increases the mechanical strength of the vessel wall, here the aortic wall 20, and further dilatation of the blood vessel (eg Aorta) and resulting complications can be avoided or prevented.
  • Lattice structure 10 causes a mechanical alteration of intima and media. Due to expansion-related injuries of the aortic wall 20 and the slight mismatch between the compliance of the lattice structure 10 and the aorta or the aortic wall 20, a foreign body reaction of the aortic wall 20 takes place
  • Implant and the aortic wall 20 a solid, almost inseparable unit with an increase in the mechanical strength of the aortic wall 20.
  • the beneficial reinforcement of the thoracic aorta is by the appropriate
  • the radial force is determined by the pattern or pattern, the cells or mesh structures and surface structures of the webs 12th
  • the surface of the implant or stent is modified by a synthetic coating, preferably of polycarbonate urethane or polyurethane.
  • Elasticity which is expedient to follow the diameter changes of the aorta during systole and diastole.
  • An oversizing of the lattice structure 10 of at most 10% advantageously causes sufficient fixation to ingrowth in the aorta. Furthermore, a homogenous lining of the aortic wall 20 by the lattice structure 10 is ensured by such oversizing.
  • the self-expanding properties of the lattice structure 10 are thereby particularly advantageous, since the radial expansion force can already be set after the implantation of the lattice structure 10 during the production process.
  • the expansion force of the self-expandable grid structure 10 is therefore independent of the implantation process. Furthermore, self-expandable materials, in particular by their pseudoelastic properties, offer high elasticity, so that an axial alignment of the lattice structure 10 in the aorta and the suitable adaptation to the change in the aortic diameter are provided.
  • the coating 13 makes it possible to accelerate the ingrowth and the endotelialization of the lattice structure 10.
  • the coating 13 enlarges the contact surface between the lattice structure 10 and the aortic wall 20
  • Coating 13 supports the penetration of fibroblasts and collagen fibers. It has been shown that polyurethane is a particularly suitable material for the
  • Polyurethane is advantageous as a highly elastic polymer for medical applications.
  • polyurethane offers good biocompatibility and hemocompatibility as well as a high mechanical strength and
  • the coating of the lattice structure 10 with polyurethane allows a homogeneous coverage of the cell structure of the lattice structure 10.
  • the coating 13 forms a basis for the development of a neo-intima, ie a new fabric structure, with high tear resistance.
  • the implantation of the medical implant is preferably carried out by a
  • the implantation catheter is adapted so that a retrograde implantation with access over the
  • the implantation catheter has a comparatively high flexibility and controllability.
  • the implantation catheter has a comparatively small cross-sectional diameter.
  • the implantation catheter has an outer diameter of at most 70%, in particular at most 60%, in particular at most 50%, in particular at most 40%, in particular at most 30%, in particular at most 20%, in particular at most 10%, larger than the cross-sectional diameter of the lattice structure 10 in the compressed state.
  • the implantation catheter may have a tip comprising an X-ray visible or fluoroscopically detectable material.
  • the lattice structure 10 at least partially comprise a radiopaque or fluoroscopically visible material. In this way, the implantation position or the position of the lattice structure 10 in the aorta can be controlled simply and accurately.
  • the delivery system or the implantation catheter is adapted such that a
  • the delivery system has a return mechanism that allows the lattice structure 10 to be compressed into the compressed one, at least from a partially expanded state
  • State recyclable and can be arranged in the feed system.
  • the invention is not limited to the application area (aorta) shown in the figure. Rather, the method according to the invention can also be used, for example, for the treatment of all peripheral vessels (eg arteries in the legs, arms, kidneys and in the neck) as well as in coronary vessels.
  • peripheral vessels eg arteries in the legs, arms, kidneys and in the neck

Abstract

L'invention concerne un implant médical pour la stabilisation endovasculaire de parois de vaisseaux, en particulier de la paroi aortique (20), comprenant une structure tubulaire en treillis (10) présentant des cellules (11) et qui sont limitées par des ponts (12), la structure en treillis (10) étant auto-expansible et présentant un revêtement (13) qui, lorsque la structure en treillis (10) est implantée, coopère avec la paroi de vaisseau, en particulier la paroi aortique (20), de telle manière que la structure en treillis (10) s'intègre dans la paroi aortique (20). L'invention concerne également un procédé de fabrication d'un tel implant.
PCT/EP2011/062853 2010-07-26 2011-07-26 Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant WO2012016886A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10170808.9 2010-07-26
EP10170808 2010-07-26

Publications (2)

Publication Number Publication Date
WO2012016886A2 true WO2012016886A2 (fr) 2012-02-09
WO2012016886A3 WO2012016886A3 (fr) 2012-05-10

Family

ID=44512846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062853 WO2012016886A2 (fr) 2010-07-26 2011-07-26 Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant

Country Status (1)

Country Link
WO (1) WO2012016886A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888414B2 (en) 2019-03-20 2021-01-12 inQB8 Medical Technologies, LLC Aortic dissection implant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562725A (en) * 1992-09-14 1996-10-08 Meadox Medicals Inc. Radially self-expanding implantable intraluminal device
US5782907A (en) * 1995-07-13 1998-07-21 Devices For Vascular Intervention, Inc. Involuted spring stent and graft assembly and method of use
US6273909B1 (en) * 1998-10-05 2001-08-14 Teramed Inc. Endovascular graft system
CA2453210A1 (fr) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Dispositifs anti-arythmie et leurs utilisations
US20070225795A1 (en) * 2006-03-24 2007-09-27 Juan Granada Composite vascular prosthesis
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888414B2 (en) 2019-03-20 2021-01-12 inQB8 Medical Technologies, LLC Aortic dissection implant

Also Published As

Publication number Publication date
WO2012016886A3 (fr) 2012-05-10

Similar Documents

Publication Publication Date Title
EP3528748B1 (fr) Prothèse vasculaire intraluminale destinée à être implantée dans le c ur ou dans des vaisseaux cardiaques d'un patient
DE69827192T2 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DE10145714B4 (de) Stent
DE60038191T2 (de) Endovaskulares gewebesystem
EP1648342B1 (fr) Endoprothèse vasculaire tressée destinée à être implantée dans un vaisseau sanguin
DE60018659T2 (de) Vorlaufende Stentdichtung mit kontrolliertem gegenüberliegenden seitlichen Führungsdrahtzugang zur Aufnahme bilateraler Gewebe
EP2809267B1 (fr) Prothèse vasculaire endoluminale
EP3203931B1 (fr) Système de prothèse vasculaire
EP3215055B1 (fr) Système d'endoprothèse couverte modulaire
EP4076275B1 (fr) Endoprothèse multiple pourvue d'une membrane
EP2922497A2 (fr) Implant vasculaire comportant une ramification latérale
EP2698130A1 (fr) Procédé de fabrication d'un implant corporel et implant corporel
EP4009920A1 (fr) Ensemble médical pour traiter des anévrismes, procédé de fabrication et système médical pour traiter des anévrismes
EP3678589A1 (fr) Système de prothèse vasculaire intraluminal
WO2014072501A2 (fr) Endoprothèses vasculaires sous forme de stent, stent, système de stents emboîtés et kit associé
WO2018220043A1 (fr) Endoprothèse à poches
EP2846733B1 (fr) Prothèse de bifurcation abdominale
EP2846731B1 (fr) Prothèse vasculaire intraluminale à fenestration in situ
DE102019121562B4 (de) Medizinische Vorrichtung zur Behandlung von Aneurysmen
WO2012016886A2 (fr) Implant médical pour la stabilisation endovasculaire de parois de vaisseaux et procédé de fabrication d'un tel implant
EP1295571A1 (fr) Implant aortique
EP1318773A2 (fr) Prothese implantable pour applications intravasculaires
DE102017123461A1 (de) Expandierbares Gefäßimplantat
EP1357859B1 (fr) Combinaison d'une endoprothese vasculaire a un element de maintien
EP2134268A1 (fr) Dispositif anastomotique et kit avec applicateur à usage chirurgical

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11748913

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11748913

Country of ref document: EP

Kind code of ref document: A2